Abstract:BTLA is a member of the immunoglobulin family thought to serve as a negative costimulatory molecule on activated T cells. Several recent studies, including the one published in this issue by del Rio and colleagues, have used BTLA-deficient mice and/or anti-BTLA antibodies to investigate the role of BTLA in regulating graft versus host reaction (GvHR) (1–3). Curiously, targeting BTLA either via genetic deletion, or blocking antibody, or agonistic antibody, all resulted in amelioration of GvHR. This suggests that BTLA may have several functions. Indeed, if BTLA’s function were solely inhibitory, agonistic antibody cross-linking should inhibit T cell function, reducing GvHR, whereas genetic deletion or antibody blockade should enhance T cell function, exacerbating GvHR. BTLA is expressed on activated T cells, B cells, dendritic cells, macrophages and some NK cells. Supporting its inhibitory effects, BTLA-deficient T cells display increased proliferation upon mitogenic stimulation and BTLA-KO mice are more susceptible to some autoimmune diseases. BTLA binds the TNFR family member herpes virus entry mediator (HVEM), which can also bind the coinhibitory receptor CD160 and the coactivating ligand LIGHT. The similar phenotype observed in HVEM-deficient and BTLA-deficient mice suggests that BTLA/HVEM is the predominant interaction on T cells (4). To interpret experiments using antibodies that target a surface molecule, it is essential to know whether a given antibody can drive depletion of the targeted cells, block the epitope for the endogenous ligand, or trigger signaling by the targeted molecule. To study the role of BTLA in GvHR, the Murphy group used BTLA-deficient mice as well as the non-depleting and presumably blocking anti-BTLA antibody 6A6 in a hematopoietic stem cell transfer model in which irradiated F1 recipients received parental bone marrow and/or splenocytes (2). Their experiments demonstrated reduced recovery of donor T cells with blocked or genetically absent BTLA, with the protective effect of 6A6 requiring direct engagement of BTLA on donor T cells. Sakoda et al., in a model of GvHR induced by transfer of donor splenocytes into either non-irradiated or lethally irradiated F1 recipients, used their own agonistic, non HVEM-blocking anti-BTLA mAb, BYK-1, and also BTLA-deficient mice (3). Similar to the Murphy model, reduced GvHR observed after transfer of BTLA-KO T cells was associated with diminished recovery of donor T cells whereas BYK-1 did not prevent T cell engraftment. Moreover, these authors demonstrated that reconstitution of BTLA-deficient T cells with a signaling-deficient BTLA molecule restored T cell survival. These 2 studies suggest that T cell-BTLA can serve as a ligand to the receptor HVEM that then delivers a pro-survival signal to T cells. Sakoda also showed that agonistic targeting of BTLA resulted in reduced cytotoxicity and cytokine production against allogenic stimuli (3). In the current study, del Rio and colleagues used their own anti-BTLA antibody, 4G12b, in non-irradiated F1 recipients of parental splenocytes, and confirmed the prevention of GvHR with no reduction in numbers of donor CD4+ and CD8+ T cells (1). Rather, they reported markedly reduced in vivo lysis of host cells and reduced production of cytokines by donor CD8+ T cells in response to alloantigen, suggesting that this agonistic antibody is preventing an alloreactive and cytotoxic pathway independently of any effects on T cell survival. Interestingly, the 6A6 used by the Murphy group and the 4G12b antibody used by del Rio recognize an overlapping epitope on BTLA, but binding of 4G12b to BTLA does not prevent BTLA from engaging HVEM (5), therefore presumably allowing BTLA to drive HVEM-mediated pro-survival effects. Moreover, their distinct Fc portions (hamster IgG for 6A6 versus rat IgG for 4G12b and BYK-1) may trigger different FcR- and complement-mediated signals which may contribute to their distinct consequences on T cell survival in vivo. Together, these 3 studies suggest that targeting BTLA is capable of reducing GvHR by alternative mechanisms depending on whether the endogenous HVEM-BTLA interaction is preserved or not (Figure 1). Figure 1 Schematic model of the dual effects of BTLA engagement Although these studies clarify the dual role of BTLA on T cells, a few issues remain unresolved. For instance, donor B cells express BTLA and may produce alloantibodies in this model. The agonistic anti-BTLA treatment may inhibit B cells either directly or indirectly by reducing T cell help such that reduced production of alloantibodies could contribute to the diminished in vivo cytotoxicity in anti-BTLA-treated animals. In addition, the contribution of interactions by remaining receptor/ligand pairs in the HVEM pathway needs to be considered. This may be challenging given the evidence of bi-directional signaling downstream of the BTLA/HVEM interaction as well as the potential contributions of HVEM binding to CD160 and LIGHT.

Targeting B and T lymphocyte attenuator regulates lupus disease development in NZB/W mice

A Novel BAFF Antagonist, BAFF-Trap, Effectively Alleviates the Disease Progression of Systemic Lupus Erythematosus in MRL/lpr Mice

Effect of BAFF blockade on the B cell receptor repertoire and transcriptome in a mouse model of systemic lupus erythematosus

B‐ and T‐Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis

Blockade of B-cell-activating Factor Suppresses Lupus-Like Syndrome in Autoimmune BXSB Mice

Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients

BCL-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation.

A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects Against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice.

OP0136 BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation

Attenuation by Targeting the B- and T-cell Attenuator.

Costimulatory blockade modifies germinal center B cell function in NZB/W F1 mice

Systemic Blockade of Probdnf Inhibited the Expansion and Altered the Transcriptomic Expression in CD3+B220+cells in MRL/lpr Lupus Mice

Targeting BLyS in Systemic Lupus Erythematosus

Restoration of Follicular T Regulatory/Helper Cell Balance by OX40L-JAG1 Cotreatment Suppresses Lupus Nephritis in NZBWF1/j Mice

Regulatory CD4+ T cells promote B cell anergy in murine lupus.

Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus

Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway

A Benzenediamine Derivate FC-99 Attenuates Lupus Nephritis in MRL/lpr Mice Via Inhibiting Myeloid Dendritic Cell-Secreted BAFF

T cell Dissimilarities in B Cell Activating Factor-Deficient Versus B Cell Activating Factor Receptor 3-Deficient Systemic Lupus Erythematosus-Prone NZM 2328 Mice as Contributors to Their Divergent Clinical Outcomes

Distinct Expression and Inhibitory Function of B and T Lymphocyte Attenuator on Human T Cells

LSO-002 the Transcriptional Factor Pbx1 Adjusts Peripheral B Cell Homeostasis to Constrain Lupus Autoimmunity